You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. MITOFUSIN AGONISTS TO TREAT NEURODEGENERATIVE DISEASE

    SBC: Mitochondria in Motion, Inc.            Topic: NINDS

    Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn II, MD Mitochondria in Motion, Inc. Washington University in St Louis School of Medicine Abstract: There are a number of rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD), for which there is no available or effective therapy and which lead to significant mor ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events

    SBC: CAPELLA IMAGING, LLC            Topic: NHLBI

    Despite the myriad major advances in cardiologythe prognosis for patients with severemedically refractive heart failureHFis exceedingly poorApproximatelydeaths occur annually in patients with HF who have endured an impaired quality of life often accompanied by significant economic and personal losses due to recurrent hospitalizationsAt leastof these deaths were directly related to severe heart fai ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    PROJECT SUMMARY There is need for an artificial oxygenOcarrier to substitute for banked blood in settings wherestored blood is unavailablepre hospital care transportaustere environmentsundeveloped countriesorundesirabletransfusion risk exceeds benefitTo address this needwe developedErythroMerEMa first inclass nano cyte blood substituteEM is a deformablecross linked polymeric nanoparticle that inco ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. An unique patient population for clinical trials against noise-induced hearing loss

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    AbstractNoise is the number one occupational and environmental hazardand noiseinduced hearing lossNIHLis one common form of sensorineural hearing deficitonly second to age related hearing lossCurrently no drug preventing NIHL is approved by the United States Food and Drug AdministrationFDAOne major challenge for the introduction of such interventions is the need to identify appropriate human popul ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Smart Sensor Bandage for Ulcer Monitoring

    SBC: STOECKER MD, WILLIAM V            Topic: 600

    AbstractSmart Sensor Bandage for Ulcer Monitoring Non healing pressure ulcers result in approximately $billion in additional treatments each year in the United Statesraising in hospital mortality by nearly threefold and lengthening hospital stay by more than double when ulcers are presentThis burden is particularly pronounced in assisted living facilities where occurrence is high and skilled nursi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Develop novel lutein biomanufacturing in a nonmodel yeast via engineered metabolons and metabolic analyses

    SBC: Arch Innotek, LLC            Topic: 300

    Project Summary Arch Innotek proposes to develop a sustainablecost effective fermentation process to produce lutein using engineered yeastLutein is an important antioxidant compound that can slow the progression of vision loss caused by age related macular degenerationAMDcataractsand retinitis pigmentosaAside from protecting eyesdietary intake of lutein can reduce risk of skin disordersseveral typ ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. ErythroMer Nanoscale Bio Synthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    PROJECT SUMMARY There is need for an artificial oxygen O carrier to substitute for banked blood in settings where stored blood is unavailable pre hospital care transport austere environments undeveloped countries or undesirable transfusion risk exceeds benefit To address this need we developed ErythroMer EM a first in class nano cyte blood substitute EM is a deformable ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Develop a new cisplatin based drug combination with reduced ototoxicity

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    PROJECT SUMMARY In spite of recent new drug developments platinum based drugs such as cisplatin are still widely used to treat solid organ malignancies Besides its limited efficacy serious side effects have been associated with the use of cisplatin such as bilateral and irreversible hearing loss In the cochlea cisplatin can trigger the production of reactive oxygen species and activate sev ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Developing a Nutraceutical Product against Noise Induce Hearing Loss

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    PROJECT SUMMARY The most common occupational and environmental hazard in this country is noise Itandapos s not surprising then that noise induced hearing loss NIHL is the second most common form of sensorineural hearing deficit behind only age related hearing loss presbycusis Although therapeutics that target the free radical pathway have shown promise for reducing NIHL there are no effe ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government